News For AES


Combining Camrelizumab and Chemotherapy Improves Overall Survival in Squamous NSCLC - Targeted Oncology

Google 5/19/2022 2:06:22 PM

Erenumab Is Well Tolerated for up to 12 Months, Study Results Show - Pharmacy Times

Google 5/19/2022 1:47:52 PM

CAPSTONE-1 demonstrates adebrelimab OS benefit for extensive-stage SCLC - medwireNews

Google 5/19/2022 9:03:14 AM

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV) | Small Molecules | News Channels - PipelineReview.com

Google 5/19/2022 6:55:48 AM

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022 - GlobeNewswire

Google 5/19/2022 6:05:22 AM

Traffic deaths up 10% in U.S., prompting calls for safety tech - FierceElectronics

Google 5/19/2022 1:53:32 AM

Tsao Picks Second-Line Therapy for a Patient With EGFR Exon 20+ NSCLC - Targeted Oncology

Google 5/19/2022 12:00:11 AM

AES Corp. stock falls Wednesday, still outperforms market - MarketWatch

Google 5/18/2022 8:34:00 PM

 1 2 3 4 5  ...  
News | Twitter | Videos | Images | Events | SiteMap
© Copyright 2011 - 2012 infoweblive.com - All Rights Reserved